-

09:50:17 PM

LLY Stock News

LLY - Lilly(Eli) & Co

12/01/22 8:41 AM

Nasdaq, NYSE : AKUS, LLY

acquisitionlow float

Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class

RHEA-AI

positive

11/30/22 6:00 PM

NYSE : LLY

Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease

- Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm ® (aducanumab-avwa)-treated patients at 6 months- Donanemab reduced brain amyloid plaque levels vs. baseline by 65.2% compared with 17.0% for Aduhelm ® at 6 monthsSAN

RHEA-AI

neutral

11/30/22 6:50 AM

NYSE, Nasdaq : LLY, AKUS

Lilly and Akouos Announce Expiration of Akouos Tender Offer

Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the

RHEA-AI

neutral

11/29/22 10:00 AM

NYSE : LLY

Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement

Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial

RHEA-AI

neutral

11/16/22 10:00 AM

NYSE : LLY

conferences

Lilly to Participate in Evercore ISI HealthCONx Conference

Eli Lilly and Company (NYSE: LLY) will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022. Jacob Van Naarden, Lilly executive vice president and CEO of Loxo@Lilly, and David Hyman, M.D., chief medical officer,

RHEA-AI

neutral

11/07/22 11:30 AM

NYSE : LLY

Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform

Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Data shared through platform interface may help healthcare providers make data-driven decisions

RHEA-AI

neutral

11/07/22 8:00 AM

NYSE : LLY, NVO

Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes

Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, today announced its Bigfoot Unity ® Diabetes Management System is now compatible with four additional rapid-acting insulin products, including two unbranded biologics. It is a critical part of our mission,” said...

RHEA-AI

neutral

11/04/22 10:30 AM

NYSE : LLY

Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

- EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice - Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing

RHEA-AI

neutral

11/03/22 9:00 AM

NYSE : LLY

Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting

Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the BRUIN Phase 1/2 trial of pirtobrutinib at the American Society of Hematology (ASH) Annual Meeting to be held December

RHEA-AI

neutral

11/01/22 6:25 AM

NYSE : LLY

earnings

Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress

Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and lower Alimta revenue following the entry of generics. Total worldwide volume in Q3 2022 increased 14%. Strong launch

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

LLY Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.lilly.com
CeoDavid Ricks
Security nameLilly(Eli) & Co
Issue typecs
SectorManufacturing
Sic code2834
Employees2021
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressLilly Corporate Ctr
StateIndiana
CityIndianapolis
Zip46285-0001
CountryUS
Phone13172762000

About Lilly(Eli) & Co

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.